Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children

Inclusion Criteria:

• Children has completed all visits and therapy in previous phase IV study;

• Investigators evaluate subjects could continue growth hormone therapy;

• Subjects is willing and able to cooperate to complete scheduled visits, treatmentplans and laboratory tests and other procedures, to sign informed consent.

Exclusion Criteria:

• Children with epiphyseal closure;

• Children is near the adule final height, that is, growth rate≤ 2 cm / year or bone age ≥ 14 years old for girls, bone age ≥ 16 years old for boys;

• Dysfunction of liver and kidney (ALT> 2 times the upper limit of normal, Cr> upperlimit of normal);

• Patients with known hypersensitivity to PEG-Somatropin or Somatropin or any othercomponents of the study product;

• Patients with severe cardiopulmonary or hematological diseases, a current or pasthistory of malignant tumors, immunodeficiency diseases, or mental diseases;

• Patients with diabetics;

• Patients with congenital bone dysplasia or scoliosis;

• Patients took drugs that would influence the efficacy and safety of PEG-Somatropinafter phase IV study and before screening for this extension study;

• Other conditions in which the investigator preclude enrollment into the study.